Encouraging results from the open label trial of Ambroxol
Ambroxol was found to be safe and well tolerated in an open label trial in 18 people with Parkinson’s. It enters the brain and appears to increase levels of its chemical target GCase.
Ambroxol was found to be safe and well tolerated in an open label trial in 18 people with Parkinson’s. It enters the brain and appears to increase levels of its chemical target GCase.
New research into the cellular clearance pathways governed by the GBA gene has shown reduced activity associated with both ageing and idiopathic Parkinson’s.